Natalie Trevaskis is an Associate Professor, Pharmacist and Heads the Lymphatic Medicine Laboratory at the Monash Institute of Pharmaceutical Sciences, Melbourne, Australia. Her research program is focussed on the role of lymphatics in acute, inflammatory and metabolic diseases, and drug delivery to the lymphatics to treat these diseases. She has extensive experience in biopharmaceutics, pharmacokinetics and delivery of a range of therapeutic types. Natalie’s research has resulted in ~90 peer reviewed papers (>8000 cites) including significant papers in Nature, Nature Metabolism, Nature Rev Drug Discovery, Nature Nano, Angew Chemie, J Control Rel etc. Natalie is also an inventor of 13 patents, including for a lymph-directing prodrug technology licensed to Puretech Health and Seaport Therapeutics with candidates in phase 1 and 2 clinical trials. Natalie has worked and consulted extensively with industry (Pfizer, Novartis, Astra Zeneca, Eli Lilly, Amgen, Genentech, Janssen, Protagonist, PureTech Health, Noxopharm etc.) to solve drug delivery problems. Natalie has received several notable academic prizes including the Gold Medal for Bachelor of Pharmacy, Mollie Hollman Doctoral Medal for PhD Thesis excellence, AK McIntyre prize from the Australian Physiological Society for early career research and Future Research Leader Award for work up to 10 years post-doc at Monash University. In 2022 and 2023 Natalie was named as a Clarivate highly cited (Hi-Ci) researcher in pharmacology (top ~0.1%).

George is completing his PhD in Pharmacoepidemiology at the Centre for Medicine Use and Safety, Monash University. His research has a methodological focus on leveraging real-world clinical data to generate and validate drug repurposing hypotheses, using traditional and emerging pharmacoepidemiologic study designs. George is also a practising pharmacist and an Assistant Lecturer at the Faculty of Pharmacy and Pharmaceutical Sciences, Monash University.

Associate Professor Edward Chia-Cheng Lai specializes in pharmacoepidemiology, with a focus on research projects using cross-center and cross-national databases. He has received solid training in research methodology. He has published approximately 90 research papers in top-tier journals, including BMJ, Annals of Internal Medicine, and Clinical Pharmacology & Therapeutics. His articles have been cited over 1,000 times. Recognized for his outstanding performance in research methodology, he was invited to become the Associate Editor of the official journal of the International Society for Pharmacoepidemiology (ISPE), Pharmacoepidemiology and Drug Safety, in 2013. He reviews over 30 research papers annually and invites more than 100 domestic and international reviewers to assist in the peer-review process, demonstrating significant academic influence.

Associate Professor Wee Hwee Lin is Director of the Centre for Health Intervention and Policy Evaluation Research (HIPER) based in the Saw Swee Hock School of Public Health at the National University of Singapore. HIPER develops capacity in health technology assessments in ASEAN through short courses and project mentoring. She is a member of the International Society for Pharmacoeconomics and Outcomes Research Health Sciences Policy Council, the International Editorial Advisory Board for Journal of Patient Reported Outcomes, and the National Advisory Committee on Cancer in Singapore. A/P Wee’s current work focuses on the use of real world evidence in health technology assessments. Specifically, this entails mining both structured and unstructured data in electronic medical records to evaluate cost-effectiveness of health technologies.